[O17] Oral Session 17　Hepatobiliary / Pancreatic Cancer
【E】

[O17-5] Lenvatinib plus HAIC with cisplatin for advanced hepatocellular carcinoma: multicenter phase II trial (LEOPARD)

^○Sadahisa Ogasawara¹, Masafumi Ikeda², Tatsuya Yamashita³, Masatoshi Kudo⁴, Yoshitaka Inaba⁵, Manabu Morimoto⁶, Kaoru Tsuchiya⁷, Satoshi Shimizu⁸, Yasushi Kojima⁹, Atsushi Hiraoka¹⁰, Kazuhiro Nouso¹¹, Hiroshi Aikata¹², Kazushi Numata¹³, Tosiya Sato¹⁴, Takuji Okusaka¹⁵, Junji Furuse¹⁶ (1.Department of Gastroenterology, Graduate School of Medicine, Chiba University, 2.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 3.Department of Gastroenterology, Kanazawa University Hospital, 4.Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, 5.Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, 6.Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, 7.Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, 8.Department of Gastroenterology, Saitama Cancer Center, 9.Department of Gastroenterology, National Center for Global health and Medicine Center Hospital, 10.Gastroenterology Center, Ehime Prefectural Central Hospital, 11.Department of Gastroenterology, Okayama City Hospital, 12.Department of Gastroenterology and Metabolism, Hiroshima University, 13.Gastroenterological Center, Yokohama City University Medical Center, 14.Department of Biostatistics, Kyoto University School of Public Health, 15.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 16.Department of Medical Oncology, Kyorin University Faculty of Medicine)